We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+4.84%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$704M
AUM Growth
+$37.8M
Cap. Flow
+$141M
Cap. Flow %
19.98%
Top 10 Hldgs %
44.68%
Holding
54
New
11
Increased
21
Reduced
11
Closed
7

Top Buys

Rank Stock Value
1
CNTX icon
Context Therapeutics
CNTX
+$25.4M
2
ZLAB icon
Zai Lab
ZLAB
+$22.2M
3
PTCT icon
PTC Therapeutics
PTCT
+$14.8M
4
SRRK icon
Scholar Rock
SRRK
+$13.6M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$11.7M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$16.3M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$15.4M
3
KALV
KalVista Pharmaceuticals
KALV
+$10.4M
4
VKTX icon
Viking Therapeutics
VKTX
+$7.66M
5
NTLA icon
Intellia Therapeutics
NTLA
+$5.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.4B
$93.2M 13.23%
7,648,268
– –
CRNX icon
2
Crinetics Pharmaceuticals
CRNX
$9B
$31.5M 4.48%
617,035
+91,190
+17% +$5.1M
EWTX icon
3
Edgewise Therapeutics
EWTX
$4.64B
$28.8M 4.09%
1,079,316
+162,150
+18% +$5.16M
INSM icon
4
Insmed
INSM
$25.9B
$26.9M 3.82%
389,611
-225,780
-37% -$16.3M
NTRA icon
5
Natera
NTRA
$47B
$25.4M 3.61%
160,626
-16,473
-9% -$2.4M
MIRM icon
6
Mirum Pharmaceuticals
MIRM
$5.94B
$24.4M 3.46%
589,579
+96,856
+20% +$4.04M
IRON icon
7
Disc Medicine
IRON
$3.07B
$22M 3.12%
346,401
+34,640
+11% +$2M
LNTH icon
8
Lantheus
LNTH
$6.58B
$21.1M 3%
236,213
+86,031
+57% +$8.38M
ZLAB icon
9
Zai Lab
ZLAB
$2.93B
$21M 2.97%
+800,000
New +$22.2M
RNAM
10
DELISTED
Avidity Biosciences
RNAM
$20.4M 2.9%
702,981
+14,006
+2% +$585K
IOVA icon
11
Iovance Biotherapeutics
IOVA
$3.63B
$19.8M 2.81%
2,673,905
+267,191
+11% +$2.48M
PTCT icon
12
PTC Therapeutics
PTCT
$5.85B
$19.6M 2.79%
434,767
+345,052
+385% +$14.8M
WVE icon
13
Wave Life Sciences
WVE
$993M
$18.4M 2.62%
1,489,237
+864,766
+138% +$11.5M
SRRK icon
14
Scholar Rock
SRRK
$7.04B
$18M 2.55%
+416,144
New +$13.6M
MLTX icon
15
MoonLake Immunotherapeutics
MLTX
$1.28B
$17.1M 2.42%
315,230
-33,833
-10% -$1.73M
OLMA icon
16
Olema Pharmaceuticals
OLMA
$899M
$17M 2.41%
2,912,550
+231,954
+9% +$2.32M
RARE icon
17
Ultragenyx Pharmaceutical
RARE
$2.52B
$16.5M 2.34%
391,018
+61,285
+19% +$3.04M
CNTX icon
18
Context Therapeutics
CNTX
$35.3M
$15.4M 2.19%
+14,705,882
New +$25.4M
GH icon
19
Guardant Health
GH
$21.7B
$13.8M 1.96%
452,739
-46,431
-9% -$1.31M
RVMD icon
20
Revolution Medicines
RVMD
$44.6B
$13.7M 1.95%
313,817
+22,426
+8% +$1.13M
ITOS
21
DELISTED
iTeos Therapeutics
ITOS
$13.4M 1.9%
1,745,943
– –
RNAC icon
22
Cartesian Therapeutics
RNAC
$290M
$12.9M 1.83%
721,139
+91,716
+15% +$1.86M
RCKT icon
23
Rocket Pharmaceuticals
RCKT
$424M
$12.8M 1.82%
1,020,559
-45,814
-4% -$690K
AKRO
24
DELISTED
Akero Therapeutics
AKRO
$12.8M 1.82%
460,617
+68,073
+17% +$2.06M
TRVI icon
25
Trevi Therapeutics
TRVI
$2.39B
$12.8M 1.81%
3,094,896
+1,556,379
+101% +$4.98M
1
2 3

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q4 2024 Portfolio in Review

As of Q4 2024, MPM BioImpact held 54 positions worth $704M, up 5.7% from $667M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

MPM BioImpact deployed $141M of net new capital in Q4 2024, opening 11 new positions and adding to 21 existing holdings. Its largest new stake was Context Therapeutics: 14,705,882 shares worth $15.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Insmed, an estimated $16.3M trimmed.

  • MPM BioImpact's largest Q4 2024 buy was Context Therapeutics: 14,705,882 shares worth $15.4M.
  • MPM BioImpact added most to PTC Therapeutics in Q4 2024, an estimated $14.8M increase.
  • MPM BioImpact's biggest Q4 2024 reduction was Insmed, cutting an estimated $16.3M.
  • MPM BioImpact fully exited Madrigal Pharmaceuticals in Q4 2024, selling an estimated $15.4M.
  • MPM BioImpact's ten largest holdings make up 45% of its $704M portfolio in Q4 2024.
  • MPM BioImpact opened 11 new positions and closed 7 in Q4 2024.
  • MPM BioImpact's portfolio value rose 5.7% quarter-over-quarter to $704M.

Based on MPM BioImpact's 13F filing for Q4 2024, filed 14 Feb 2025.